scanner. ParaVision 5.1 was used to analyze regions of interest (ROI) and fractional anisotropy (FA), axial diffusivity (AD ( l1)), and radial diffusivity (RD ([l2+ l3]/2)) were measured. To compare two groups a Student's t-test was used and for multiple group comparisons a two-way ANOVA with Tukey post-hoc test was performed (n¼5/group). RESULTS: CHORIO impaired thalamic microstructure and increased FA by 45% compared to sham (0.253AE0.03 vs. 0.174AE0.003, p¼0.03). CHORIO also reduced thalamic AD by 14% and RD by 19% compared to sham (p¼0.05 and p¼0.08 respectively). Notably, treatment with EPO+MLT restored thalamic FA in CHORIO rats and attenuated injury induced changes in diffusion (0.185AE0.01 vs. 0.253AE0.03, p¼0.05). CONCLUSION: CHORIO results in impaired microstructure and aberrant directional diffusion in the adult rat thalamus. These changes in structural coherence may be responsive to neurorepair by postnatal EPO+MLT therapy. The thalamus plays a major role in gating and neural networks between various subcortical and cortical areas and injury to this vital structure could play a role in deficits in cognition and pain processing. Additional investigations are needed to determine the mechanisms of injury to facilitate future biomarker and therapeutic target discovery.
Maternal and neonatal outcomes associated with early amniotomy in term nulliparous labor induction
Ashley N. Battarbee for the Eunice Kennedy Shriver NICHD Maternal-Fetal Medicine Units Network, Bethesda, MD OBJECTIVE: To evaluate the association between timing of amniotomy and maternal and neonatal outcomes among nulliparous women undergoing labor induction at term. STUDY DESIGN: A secondary analysis of a randomized trial of labor induction at 39 weeks versus expectant management in low-risk, nulliparous women (2014) (2015) (2016) (2017) . Women who underwent labor induction with early artificial rupture of membranes (AROM), defined as AROM < 5cm cervical dilatation, were compared to women who did not have early AROM. Women with antepartum stillbirth and spontaneous rupture of membranes < 5cm cervical dilatation were excluded. Our primary outcome was cesarean delivery. Secondary outcomes included chorioamnionitis, duration of labor > 24 hours, overall pain score > 5 (out of 10), maternal hospitalization > 3 days, postpartum hemorrhage, postpartum infection, NICU admission, and composite neonatal morbidity, as defined in the parent trial. We used bivariable analysis to compare maternal and obstetric characteristics by early AROM and multivariable logistic regression modeling to estimate adjusted odds ratios for the relationship between early AROM and the primary and secondary outcomes. RESULTS: Of 6,106 women enrolled in the parent trial, 2513 (41%) met inclusion criteria for this analysis: 1517 (60.4%) women had early AROM and 996 (39.6%) did not. Women with early AROM were older, more likely to be non-Hispanic white, married, privately insured, more likely to be electively induced and less likely to receive Foley balloon or prostaglandins for cervical ripening (Table 1) . Early AROM was associated with higher adjusted odds of cesarean, chorioamnionitis, duration of labor > 24 hours, maternal hospitalization > 3 days, and postpartum infection (Table 2 ). There was no significant association between early AROM and maternal pain score > 5, postpartum hemorrhage, or adverse neonatal outcomes (Table 2) .
CONCLUSION: Among a contemporary cohort of nulliparous women undergoing labor induction at term, early AROM < 5cm cervical dilatation was associated with higher odds of certain maternal outcomes including cesarean delivery, chorioamnionitis, duration of labor, length of maternal hospitalization, and postpartum infection, but not with any neonatal outcomes. Additional analyses of early AROM, defined as a time interval since the start of labor induction, are needed to better understand the difference between these results and prior findings.
47 Impact of delayed cord clamping on maternal blood loss in term cesareans: a randomized trial OBJECTIVE: The American College of Obstetricians and Gynecologists recommends a delay in umbilical cord clamping in term infants for at least 30-60 sec after birth, irrespective of mode of delivery. However, most literature supporting this practice is from low risk vaginal deliveries (VD). There are no published data specific to women (or neonates) undergoing cesarean delivery (CD), where the mean blood loss is twice that of a VD with the potential for increased bleeding from delayed hysterotomy closure. We performed a randomized trial to compare maternal blood loss with immediate cord clamping (ICC) versus delayed cord clamping (DCC) in term CD. STUDY DESIGN: Two-center, randomized clinical trial comparing maternal blood loss with ICC ( 15 sec after birth) versus DCC (60 sec after birth) in term CD (NCT03150641). Women undergoing scheduled CD of full term singleton gestations were eligible. Those with abnormal placentation, fetal anomalies, known fetal anemia, growth restriction with abnormal Dopplers, preeclampsia, significant maternal anemia, bleeding disorders, planned cord blood banking or refusal of blood products were excluded. Immediately before CD, women were randomized in a 1:1 ratio to ICC or DCC. The primary outcome was drop in maternal hemoglobin (Hgb) from pre-op to post-op day one. Secondary maternal outcomes included estimated blood loss, postpartum hemorrhage (>1000 mL), need for uterotonics and blood transfusion. Neonatal outcomes including Hgb at 24-72 hrs of life were assessed. Assuming a mean Hgb drop of 1.37 AE 0.87 g/dL, with a hypothesized effect size of a 0.9 g/dL (1.25 SD) difference in the primary outcome between groups and anticipating 20% crossover, the required sample size (two-tailed a¼0.05, b¼0.1; 90% power) was 53 women per group. Analysis was based on intention-to-treat. RESULTS: From October 2017 -February 2018, 113 women were randomized (56 to ICC; 57 to DCC). There was no difference in the primary outcome, with a mean drop in Hgb of 1.78 AE 0.91 g/dL and 1.85 AE 0.95 g/dL in the ICC and DCC groups (P¼0.69, Table 1 ). Maternal secondary outcomes were similar between groups. Neonatal Hgb data, available for 90 infants (79.6%), showed a higher Hgb with DCC compared to ICC (18.1 AE 2.5 vs 16.4 AE 1.9 g/dL; P <0.01; Table 2 ). CONCLUSION: In scheduled term CD, DCC is not associated with increased maternal blood loss but does achieve higher neonatal Hgb levels at 24-72 hrs of life.
48 Effect of obesity on platelet inhibition in highrisk pregnant women treated with low dose aspirin OBJECTIVE: Low dose aspirin (LDA) is used for preeclampsia (PE) prevention in high risk women, but the precise mechanism and optimal dose is not known. Evidence suggests that an imbalance in prostacyclin and thromboxane A 2 (TxA 2 ) plays a key role in PE. Aspirin (ASA) has a dose-dependent effect blocking production of TxA 2 , a potent stimulator of platelet aggregation (PA) and promoter of vasoconstriction. Incomplete inhibition of PA, designated aspirin resistance (AR), can be reduced by increasing the ASA dose. Evidence in the non-obstetric literature suggests AR may be more common among patients with a high body mass index (BMI). This study examines the impact of obesity on platelet responsiveness in high risk women treated with LDA. STUDY DESIGN: Secondary analysis of a prospective multi-centered study investigating the effect of LDA (60mg) administration in women at high risk of PE. Maternal serum TxB 2 (an indirect measure of TxA 2 ) levels were drawn at three time points: randomization, 24-28, and 34-38 weeks' gestation. Patients were included in the analysis if they had at least one TxB 2 level after randomization. Patients were stratified by BMI categories (<30, 30-39, !40) and treatment arm (LDA vs. placebo). Median TxB 2 levels were calculated at each time point as well as rates of complete TxB 2 inhibition (<0.01 ng/mL). A multivariate logistic regression was performed to generate odds ratios (OR) for complete TxB 2 inhibition by BMI category adjusting for race, high risk group at randomization & nulliparity. RESULTS: There were 1018 patients included in the analysis, 505 (49.6%) and 513 (50.4%) in the LDA & placebo groups respectively. Median TxB 2 levels were significantly increased in women with a BMI !40 in both the LDA & placebo groups; Fig. 1 . There were substantial decreases in TxB 2 levels among LDA treated women in all BMI categories, but rates of complete TxB 2 inhibition were lowest in patients with BMI !40 when compared to BMI <30 and 30-39; Table 1 . Overall, odds of complete inhibition of TxB 2 were reduced in women with BMI !40 at both 24-28 (OR 0.45; CI 0.22-0.94) and 34-38 (OR 0.40; CI 0.16-0.97) weeks' gestational age, but not with BMI 30-39 when compared to BMI <30. CONCLUSION: LDA substantially lowers TxB 2 levels regardless of BMI, but rates of complete platelet inhibition are lower in women with BMI !40. This data suggests that higher doses of ASA may be necessary in obese women.
